Decorin: matrix-based pan-cancer tumor suppressor

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Decorin is a potent pan-cancer tumor suppressor that is underexpressed in most malignancies.
• It functions as a pan-receptor tyrosine kinase inhibitor, suppressing oncogenic signaling pathways.
• Decorin deficiency is linked to increased epithelial-to-mesenchymal transition, cancer dissemination, and metastasis.

Purpose of the Study:

• To outline the expressional and clinicopathological significance of decorin in major human cancers.
• To review decorin's potential as a molecular marker and therapeutic agent for cancer management.
• To assess the translational potential of decorin's tumor-suppressive actions from preclinical to clinical settings.

Main Methods:

• Review of available preclinical and clinical studies on decorin in major cancers.
• Analysis of decorin's interaction with receptor tyrosine kinases.
• Evaluation of plasma decorin measurement as a minimally invasive prognostic tool.

Main Results:

• Decorin deficiency promotes cancer progression and metastasis.
• Plasma decorin levels may predict clinical outcomes in cancer patients, requiring further validation.
• Oncolytic virus-mediated decorin gene transfer and exogenous decorin delivery show preclinical anti-tumorigenic effects.

Conclusions:

• Decorin holds significant promise as a pan-cancer tumor suppressor and potential therapeutic target.
• Further research is essential to validate plasma decorin as a biomarker and translate decorin-based therapies into clinical practice.
• Understanding decorin's therapeutic efficacy and safety is crucial for its clinical application.